美国Genta
Genta（Nasdaq 上市代码 GNTA 一家专门开发抗癌药物的生物科技公司）－ 1998年Genta这个的由大众投资的上市公司宣布失败，并且当时市值只有500万美元。在这种情况下Oyler先生被邀请担任这个公司的CEO。 在担任CEO后Oyler先生为公司争取到了新的资金，重新启动了7个临床的项目并聘请了全新的管理团队。由于Oyler先生的出色工作，Genta的业绩稳步提高，逐渐走出了低谷。 目前Genta的市值为16亿美元。


Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform : DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta has completed enrollment to the AGENDA Trial , a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection) , which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite® and Genasense® are available on a ”named-patient“ basis in countries outside the United States.

Genta is committed to improving the lives of patients by providing innovative solutions in the treatment of cancer. Our team of scientists, physicians and business people have extensive experience in the identification, development and commercialization of oncology products.